Oncology
Malignant Solid Tumors
0
Pipeline Programs↗
24
Active Trials↗
14
Companies Involved↗
Malignant Solid Tumors is an early-stage landscape with 0 programs across 14 companies. The most active players are Genmab, Immorna Biotherapeutics, Inc., Suzhou Suncadia Biopharmaceuticals Co., Ltd..
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
No pipeline programs currently tracked for this disease.
Analysis
Trial Status
48
clinical trials
Recruiting13 · 27%
Completed12 · 25%
Not yet recruiting6 · 13%
Terminated6 · 13%
Unknown status5 · 10%
Active, not recruiting4 · 8%
Other2 · 4%
Clinical Trials
Trial Activity
48 trials
Study of RGL-270 Single Drug and Combined With Adebelimab in Patients in Patients at High Risk of Recurrence After Radical Treatment of Malignant Solid Tumors
Recruiting·—·Phase 1·NCT07348042·198 enrolled
Intestinal Low Dose Radiotherapy Combined With Immunotherapy in Immune-resistant Metastatic Malignant Solid Tumors
Recruiting·—·Phase 2·NCT07071103·48 enrolled
Page 1 of 4
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)